Keyword Connections

doi:10.1111/j.1365-2036.2011.04827.x

Journals

0

No Journal Connected

Research Groups

0

No Research Group Connected

Bibliographies

1

1 Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease